Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aardvark Therapeutics Announces $85M Series C Financing | Contract Pharma

What are you searching for?

Sign in
Breaking News

Aardvark Therapeutics Announces $85M Series C Financing

Will use the proceeds from the financing to advance the regulatory approval of its lead asset, ARD-101.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Aardvark Therapeutics Inc. has announced an $85 million oversubscribed Series C financing led by Decheng Capital, with participation from Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Fitzgerald & Co., Silver Arc Private Capital, The Prader-Willi Syndrome Association – USA, and existing investors, including Vickers Venture Partners and the Foundation for Prader-Willi Research. 
 
Aardvark intends to use the proceeds from the financing to complete the clinical trials required for regulatory approval of Aardvark’s lead asset, ARD-101, for the treatment of hyperphagia in patients with Prader-Willi Syndrome, demonstrate ARD-101’s complementary mechanism of action to the current GLP-1 therapies in the treatment of obesity and advance other Aardvark pipeline programs.
 
Aardvark Therapeutics CEO, Tien Lee, M.D., commented: “We believe our lead compound, ARD-101, is a well-differentiated first-in-class drug candidate that is orthogonal and complementary to existing obesity drugs and reduces hunger through the selective induction of gut-brain signaling. The novel mechanism of action and gut-restricted nature of ARD-101 contribute to its encouraging safety and tolerability profile, as well as its broad-spectrum of activity. We are excited that our new and existing investors share our vision of ARD-101’s potential therapeutic impact and the relevance of TAS2R receptors as unique pharmaceutical targets.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics